Rankings
▼
Calendar
VCEL
Vericel Corporation
$2B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$58M
+27.0% YoY
Gross Profit
$42M
71.9% margin
Operating Income
-$2M
-4.3% margin
Net Income
-$901,000
-1.6% margin
EPS (Diluted)
$-0.02
QoQ Revenue Growth
+10.0%
Cash Flow
Operating Cash Flow
$10M
Free Cash Flow
$41M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$390M
Total Liabilities
$133M
Stockholders' Equity
$257M
Cash & Equivalents
$54M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$58M
$46M
+27.0%
Gross Profit
$42M
$31M
+36.1%
Operating Income
-$2M
-$5M
+51.3%
Net Income
-$901,000
-$4M
+75.4%
Revenue Segments
MACI Implants And Kits
$45M
100%
← FY 2024
All Quarters
Q4 2024 →
VCEL Q3 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena